Clinical Trials Logo
  1. Home
  2. ITP
  3. NCT04089267

Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

ITP Clinical Trial

Official title:
Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

Clinical Trial Summary

This is a review of the efficacy and safety of different recombinant human thrombopoietin (rhTPO) regimens in the treatment of patients with primary immune thrombocytopenia (ITP).

Clinical Trial Description

Evaluating the efficacy and safety of different human thrombopoietin (rhTPO) regimens in the treatment of patients with primary immune thrombocytopenia (ITP) This trial was designed as a multicenter, randomized, open, parallel controlled study ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04089267
Study type Interventional
Source Shenyang Sunshine Pharmaceutical Co., LTD.
Contact
Status Completed
Phase Phase 4
Start date December 2016
Completion date August 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05281068 - The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia Phase 2
Recruiting NCT05635266 - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02914054 - Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone Phase 2/Phase 3
Recruiting NCT05116423 - Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia
Terminated NCT04904276 - Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Recruiting NCT04747080 - The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia Phase 2
Not yet recruiting NCT04482777 - IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP
Recruiting NCT05446831 - Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia Phase 2
Active, not recruiting NCT04703621 - The DART Study- Daratumumab Treatment in ITP Phase 2
Recruiting NCT05118126 - Gut Microbiota in ITP
Recruiting NCT05315778 - Anti-BCMA CAR T-Cell Therapy for R/R ITP Phase 2
Active, not recruiting NCT04943042 - An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
Recruiting NCT04735588 - Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP